---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-24-001068"
form_type: "8-K"
ticker: "ABUS"
cik: "0001447028"
company_name: "Arbutus Biopharma Corp"
filed_at: "2024-02-29T23:59:59+00:00"
generated_at: "2026-06-05T06:30:13.739142+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Arbutus Biopharma reports FY2023 net loss of $72.8M; cash runway into Q1 2026

## Summary
- Net loss $72.8M ($0.44/sh) vs $69.5M ($0.46/sh) in FY2022; revenue fell to $18.1M from $39.0M.
- Cash, cash equivalents and investments $132.3M at Dec 31, 2023; 2024 net cash burn guided $63-67M.
- Moderna LNP litigation claim construction held Feb 8, 2024; trial set for April 21, 2025.
- Phase 2a imdusiran combo data readouts expected H1 2024; third imdusiran Phase 2a trial to start H1 2024.
- AB-101 Phase 1a/1b preliminary data (healthy subjects) expected H1 2024.

## SEC filing metadata
- accession: 0001171843-24-001068
- form_type: 8-K
- ticker: ABUS
- cik: 0001447028
- company_name: Arbutus Biopharma Corp
- filed_at: 2024-02-29T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1447028/000117184324001068/0001171843-24-001068-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1447028/000117184324001068/f8k_022924.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-24-001068
- JSON: https://secwatch.observer/filing/0001171843-24-001068.json
- Plain text: https://secwatch.observer/filing/0001171843-24-001068.txt

## Key facts
- Earnings Releases
  Arbutus Biopharma Corp reported financial results for Fourth quarter and year ended December 31, 2023.
  - Period: Fourth quarter and year ended December 31, 2023
  - Result: reported results
  source text: On February 29, 2024, Arbutus Biopharma Corporation (the “Company”) issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2023 and certain other information.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1447028/000117184324001068/0001171843-24-001068-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.